Protara Therapeutics (TARA)
NASDAQ:TARA
Want to see TARA full AI Analyst Report?
TARA Stock Chart & Stats
$5.13
-$0.26(-4.26%)
At close: 4:00 PM EST
$5.13
-$0.26(-4.26%)
Day’s Range― - ―
52-Week Range$2.77 - $7.82
Previous CloseN/A
Volume145.20K
Average Volume (3M)794.40K
Market Cap
$281.78M
Enterprise Value$151.67M
Total Cash (Recent Filing)$155.55M
Total Debt (Recent Filing)$3.36M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Apr 30, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding54,084,377
10 Day Avg. Volume478,330
30 Day Avg. Volume794,404
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-837.93
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$26.00Price Target Upside406.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInterim data indicate strong complete responses and meaningful lesion resolution in bladder cancer and lymphatic malformations, suggesting competitive effectiveness that could drive clinical adoption if durability holds.
Commercial OpportunityDistinct mechanism, manageable safety, and straightforward intravesical administration position the therapy as a practical alternative to BCG amid supply constraints, supporting potential market uptake in both common and rare indications.
Regulatory PathwayFDA alignment to permit a randomized pivotal trial versus physician's choice intravesical chemotherapy establishes a clearer registration path with a prespecified primary endpoint, reducing regulatory ambiguity for approval.
Bears Say
Competitive Benchmark RiskA pending readout from a gemcitabine/docetaxel study and headline response shortfalls in small cohorts raise the chance of unfavorable comparisons that may weigh on investor sentiment and market positioning.
Durability UncertaintyLonger-term durability data remain immature and less interpretable, creating uncertainty about whether early responses will persist and increasing risk around the final efficacy readout.
Financing RiskNegative operating cash flow and absence of product revenue imply dependence on external financing, which could pressure execution and stock performance if development timelines slip.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics’s price range in the past 12 months?
Protara Therapeutics lowest stock price was $2.77 and its highest was $7.82 in the past 12 months.
What is Protara Therapeutics’s market cap?
Protara Therapeutics’s market cap is $281.78M.
When is Protara Therapeutics’s upcoming earnings report date?
Protara Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 12 days.
How were Protara Therapeutics’s earnings last quarter?
Protara Therapeutics released its earnings results on Mar 10, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.311 by -$0.059.
Is Protara Therapeutics overvalued?
According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued.
Does Protara Therapeutics pay dividends?
Protara Therapeutics does not currently pay dividends.
What is Protara Therapeutics’s EPS estimate?
Protara Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Protara Therapeutics have?
Protara Therapeutics has 54,084,377 shares outstanding.
What happened to Protara Therapeutics’s price movement after its last earnings report?
Protara Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.311. Following the earnings report the stock price went down -0.696%.
Which hedge fund is a major shareholder of Protara Therapeutics?
Currently, no hedge funds are holding shares in TARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protara Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (406.82% Upside)
$26.00 (406.82% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.94%
12-Months-Change
Fundamentals
Return on Equity
-36.38%
Trailing 12-Months
Asset Growth
15.44%
Trailing 12-Months
Company Description
Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
TARA Stock 12 Month Forecast
Average Price Target
$26.00
▲(406.82% Upside)
Technical Analysis
Protalix
―
TuHURA Biosciences
―
Skye Bioscience
―
Orchestra BioMed Holdings
―
Zura Bio
―
Ownership Overview
3.17% Insiders
6.03% Mutual Funds
<0.01% Other Institutional Investors
82.08% Public Companies and Individual Investors
Options Prices
Currently, No data available
---